Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1
Pockaj BA, Gallagher JG, Loprinzi CL, Stella PJ, Barton DL, Sloan JA, et al.
Published in J Clin Oncol, Vol. 24 (18), pp. 2836-41
Methodology
Phase III double-blind, randomised, placebo-controlled crossover trial (NCCTG N01CC1) with two 4-week periods; black cohosh 20 mg twice daily; daily hot flash diaries scored by severity.
Key Findings
132 women randomised. Hot flash score fell 20% on black cohosh versus 27% on placebo (P = .53); frequency fell 17% versus 26% (P = .36). 34% preferred black cohosh, 38% placebo and 28% neither. Toxicity was minimal and similar between arms.
Conclusions
The trial found no evidence that black cohosh reduced hot flashes more than placebo.
Limitations
Short treatment periods (4 weeks each); crossover design assumes no carry-over.
Supplements Studied
failed to provide any evidence that black cohosh reduced hot flashes more than the placebo
Outcomes Measured
failed to provide any evidence that black cohosh reduced hot flashes more than the placebo
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.